PharmApprove Founder Pete Taft to Present at Pharmaceutical Regulatory Affairs Conference
Princeton, NJ, October 23, 2010 --(PR.com)-- Pete Taft, Founder and CEO of Princeton-based drug development communications firm PharmApprove, has been asked to present and lead a session at the largest global gathering of the pharmaceutical regulatory profession.
The 2010 Regulatory Affairs Professionals Society (RAPS) Annual Conference & Exhibition offers over 2,000 participants an opportunity to network, share expertise and attend over 70 presentations and learning sessions.
On Tuesday, October 26, Pete Taft will lead the highly anticipated session on FDA Advisory Committee Meeting Preparation. As the advisory committee process has become increasingly critical in the drug development and approval process, the session will focus on the results of a qualitative research study conducted by PharmApprove, which provides insights into how Advisory Committee members think, act and vote. Taft will also present best practices and tips he and his colleagues have amassed in their 10+ years helping prepare drug development teams for hearings in the United States and overseas.
“The Advisory Committee dynamic has changed dramatically over the last 10 years,” explains Taft, whose firm helped pioneer the field of Advisory Committee preparation. “The conference will provide industry leaders from around the world with a chance to exchange new ideas and experiences all in an effort to improve the regulatory process.”
Taft will co-lead the FDA Advisory Committee Meeting Preparation session with Robert Befus, CEO of Presentation Strategies, Inc. and Interactive Holdings, LLC.
The 2010 RAPS Conference also offers sessions from top officials from the FDA and Department of Justice in the United States, as well as from regulatory agencies from Europe, China, Japan, Brazil, Canada and more. The conference will open with a keynote presentation by Vijay Govindarajan, innovation expert and professor at Dartmouth University’s Tuck School of Business. The conference will be held from October 24-27 in San Jose, CA.
About PharmApprove™
PharmApprove™ is a drug development communications company headquartered in Princeton, New Jersey. PharmApprove™ helps development teams deliver clear, consistent and compelling key messages to regulatory bodies in both the US and Europe.
PharmApprove™ works in partnership with development teams to create the strongest argument for approval at every stage of the development process when organizations have one chance to get it right. Over the last decade,
PharmApprove™ teams have helped to create and deliver over 42 drug development communications programs across 18 therapeutic areas both in the US and overseas, including more than 30 Advisory Committee preparation projects.
Currently, PharmApprove teams are helping to prepare four drug and device teams for upcoming Advisory Committee hearings, providing services including strategy development, medical writing, presentation coaching, slide creation, and project management.
PharmApprove is a division of Taft and Partners, a marketing and corporate communications firm also located in Princeton, NJ.
About Pete Taft
Pete Taft is the Founder & CEO of PharmApprove™. Pete has been the driving force behind the creation and delivery of over 42 drug development communications programs across 18 therapeutic areas both in the US and overseas, including more than 30 Advisory Committee preparation projects. Globally, Pete is frequently called upon to prepare executives and their teams for critical, often high-profile events, both within and beyond the pharmaceutical industry. Pete brings an unmatched understanding of communications theory to his work. Trained as a journalist, he covered crime, politics and law both nationally and internationally for major magazines (Reader’s Digest, Ladies’ Home Journal, Playboy) and newspapers (the New York Times, the Philadelphia Inquirer). He later served as a senior communications executive in both the public and private sectors, advising corporate executives, governors, and members of Congress on strategic communications planning, public speaking and public/media relations.
###
The 2010 Regulatory Affairs Professionals Society (RAPS) Annual Conference & Exhibition offers over 2,000 participants an opportunity to network, share expertise and attend over 70 presentations and learning sessions.
On Tuesday, October 26, Pete Taft will lead the highly anticipated session on FDA Advisory Committee Meeting Preparation. As the advisory committee process has become increasingly critical in the drug development and approval process, the session will focus on the results of a qualitative research study conducted by PharmApprove, which provides insights into how Advisory Committee members think, act and vote. Taft will also present best practices and tips he and his colleagues have amassed in their 10+ years helping prepare drug development teams for hearings in the United States and overseas.
“The Advisory Committee dynamic has changed dramatically over the last 10 years,” explains Taft, whose firm helped pioneer the field of Advisory Committee preparation. “The conference will provide industry leaders from around the world with a chance to exchange new ideas and experiences all in an effort to improve the regulatory process.”
Taft will co-lead the FDA Advisory Committee Meeting Preparation session with Robert Befus, CEO of Presentation Strategies, Inc. and Interactive Holdings, LLC.
The 2010 RAPS Conference also offers sessions from top officials from the FDA and Department of Justice in the United States, as well as from regulatory agencies from Europe, China, Japan, Brazil, Canada and more. The conference will open with a keynote presentation by Vijay Govindarajan, innovation expert and professor at Dartmouth University’s Tuck School of Business. The conference will be held from October 24-27 in San Jose, CA.
About PharmApprove™
PharmApprove™ is a drug development communications company headquartered in Princeton, New Jersey. PharmApprove™ helps development teams deliver clear, consistent and compelling key messages to regulatory bodies in both the US and Europe.
PharmApprove™ works in partnership with development teams to create the strongest argument for approval at every stage of the development process when organizations have one chance to get it right. Over the last decade,
PharmApprove™ teams have helped to create and deliver over 42 drug development communications programs across 18 therapeutic areas both in the US and overseas, including more than 30 Advisory Committee preparation projects.
Currently, PharmApprove teams are helping to prepare four drug and device teams for upcoming Advisory Committee hearings, providing services including strategy development, medical writing, presentation coaching, slide creation, and project management.
PharmApprove is a division of Taft and Partners, a marketing and corporate communications firm also located in Princeton, NJ.
About Pete Taft
Pete Taft is the Founder & CEO of PharmApprove™. Pete has been the driving force behind the creation and delivery of over 42 drug development communications programs across 18 therapeutic areas both in the US and overseas, including more than 30 Advisory Committee preparation projects. Globally, Pete is frequently called upon to prepare executives and their teams for critical, often high-profile events, both within and beyond the pharmaceutical industry. Pete brings an unmatched understanding of communications theory to his work. Trained as a journalist, he covered crime, politics and law both nationally and internationally for major magazines (Reader’s Digest, Ladies’ Home Journal, Playboy) and newspapers (the New York Times, the Philadelphia Inquirer). He later served as a senior communications executive in both the public and private sectors, advising corporate executives, governors, and members of Congress on strategic communications planning, public speaking and public/media relations.
###
Contact
Taft and Partners
Katherine Zimoulis
609-683-0700
www.taftandpartners.com
Katherine Zimoulis
609-683-0700
www.taftandpartners.com
Contact
Categories